CN115605197A - 罗非考昔的新剂型和相关方法 - Google Patents

罗非考昔的新剂型和相关方法 Download PDF

Info

Publication number
CN115605197A
CN115605197A CN202080092241.7A CN202080092241A CN115605197A CN 115605197 A CN115605197 A CN 115605197A CN 202080092241 A CN202080092241 A CN 202080092241A CN 115605197 A CN115605197 A CN 115605197A
Authority
CN
China
Prior art keywords
formulation
rofecoxib
achieves
mean
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092241.7A
Other languages
English (en)
Chinese (zh)
Inventor
B.C.西皮
R.D.斯科维尔钦斯基
T.E.赫尔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temero Pharmaceutical Co ltd
Original Assignee
Temero Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temero Pharmaceutical Co ltd filed Critical Temero Pharmaceutical Co ltd
Publication of CN115605197A publication Critical patent/CN115605197A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080092241.7A 2019-11-13 2020-11-12 罗非考昔的新剂型和相关方法 Pending CN115605197A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962934898P 2019-11-13 2019-11-13
US62/934,898 2019-11-13
US202063018136P 2020-04-30 2020-04-30
US63/018,136 2020-04-30
US16/867,514 2020-05-05
US16/867,514 US10945992B1 (en) 2019-11-13 2020-05-05 Dosage forms of rofecoxib and related methods
PCT/US2020/060152 WO2021097038A1 (en) 2019-11-13 2020-11-12 Novel dosage forms of rofecoxib and related methods

Publications (1)

Publication Number Publication Date
CN115605197A true CN115605197A (zh) 2023-01-13

Family

ID=74870322

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092241.7A Pending CN115605197A (zh) 2019-11-13 2020-11-12 罗非考昔的新剂型和相关方法

Country Status (9)

Country Link
US (5) US10945992B1 (cg-RX-API-DMAC10.html)
EP (1) EP4058012A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023502941A (cg-RX-API-DMAC10.html)
KR (1) KR20220123224A (cg-RX-API-DMAC10.html)
CN (1) CN115605197A (cg-RX-API-DMAC10.html)
CA (1) CA3155900A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022005813A (cg-RX-API-DMAC10.html)
TW (1) TW202128144A (cg-RX-API-DMAC10.html)
WO (1) WO2021097038A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210124188A (ko) * 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2023059698A1 (en) * 2021-10-06 2023-04-13 Tremeau Pharmaceuticals, Inc. Methods and compositions for treating von willebrand's migraine disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
WO2005025564A1 (en) * 2003-09-18 2005-03-24 Nobel Ilac Sanayii A.S Oral pharmaceutical formulations of rofecoxib
US20070099926A1 (en) * 2003-07-02 2007-05-03 Rodger Ian W Combination therapy for treating chronic inflammatory diseases
CN104173359A (zh) * 2014-09-05 2014-12-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
CN107614061A (zh) * 2014-12-01 2018-01-19 阿科莱尔斯疗法公司 用于治疗与疼痛有关的偏头痛和病症方法和组合物
CN113660934A (zh) * 2018-11-21 2021-11-16 特默罗制药股份有限公司 罗非昔布的纯化形式、制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21042A (en) 1858-07-27 yerby
US21647A (en) 1858-10-05 Construction of animal-traps
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
MY119407A (en) 1993-06-24 2005-05-31 Merck Frosst Canada Inc 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor.
AU1269495A (en) 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
DE69512930T2 (de) 1994-10-27 2000-05-18 Merck Frosst Canada & Co., Halifax Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AU3004997A (en) 1996-05-17 1997-12-09 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
JP4659190B2 (ja) 2000-08-31 2011-03-30 アンリツ株式会社 波形測定装置
ES2214129B1 (es) 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
WO2005016906A1 (en) 2003-08-14 2005-02-24 Shasun Chemicals And Drugs Limited Process for the manufacture of rofecoxib
US9763912B2 (en) * 2013-10-30 2017-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
WO2019193417A1 (en) 2018-04-05 2019-10-10 Kossen Co., Ltd. Composition and method of reducing joint pain associated with hemarthrosis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
US20070099926A1 (en) * 2003-07-02 2007-05-03 Rodger Ian W Combination therapy for treating chronic inflammatory diseases
WO2005025564A1 (en) * 2003-09-18 2005-03-24 Nobel Ilac Sanayii A.S Oral pharmaceutical formulations of rofecoxib
CN104173359A (zh) * 2014-09-05 2014-12-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
CN107614061A (zh) * 2014-12-01 2018-01-19 阿科莱尔斯疗法公司 用于治疗与疼痛有关的偏头痛和病症方法和组合物
CN113660934A (zh) * 2018-11-21 2021-11-16 特默罗制药股份有限公司 罗非昔布的纯化形式、制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAVEEN AHUJA等: ""Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects"", 《JOURNAL OF PHARMACY AND PHARMACOLOGY》, vol. 55, no. 7, pages 859 - 894 *

Also Published As

Publication number Publication date
US20220409575A1 (en) 2022-12-29
MX2022005813A (es) 2022-08-16
US10945992B1 (en) 2021-03-16
CA3155900A1 (en) 2021-05-20
US20210137878A1 (en) 2021-05-13
WO2021097038A1 (en) 2021-05-20
US20210169845A1 (en) 2021-06-10
KR20220123224A (ko) 2022-09-06
JP2023502941A (ja) 2023-01-26
EP4058012A1 (en) 2022-09-21
US20220047542A1 (en) 2022-02-17
TW202128144A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
JP7526143B2 (ja) 好酸球性食道炎を処置する方法
US20220409575A1 (en) Dosage forms of rofecoxib and related methods
US11458111B2 (en) Ketogenic diet compatible fenfluramine formulation
US20240277669A1 (en) Non-sedating dexmedetomidine treatment regimens
CA3230291A1 (en) Dosing regimens associated with extended release paliperidone injectable formulations
US20190133977A1 (en) Delayed release oral tamsulosin hydrochloride
US20230414618A1 (en) Methods of Administering Elagolix
CN115515592A (zh) 施用恶拉戈利的方法
JP2024539949A (ja) ボクセロトールを投与する方法
US20210137903A1 (en) Anti-androgens for the treatment of prostrate cancer
EP3473245A1 (en) Controlled release oral tamsulosin hydrochloride
US20240024322A1 (en) Methods of Administering Belumosudil in Combination with CYP3A Inducers and/or Proton Pump Inhibitors
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use
US20250312331A1 (en) Compositions and methods for administering paltusotine to patients with hepatic impairment
RU2778848C2 (ru) Состав фенфлурамина, совместимый с кетогенной диетой
TW202402293A (zh) 貝魯舒地爾與ｃｙｐ３ａ誘導劑和／或質子泵抑制劑組合投予的方法
JP2025523098A (ja) ３，５－ジヨードチロプロピオン酸組成物及びその使用方法
WO2025076350A1 (en) Methods of administering belumosudil in combination with transport protein substrates
EP3473244A1 (en) Controlled release oral tamsulosin hydrochloride
Markham Anti-androgen (L02BB04)
MXPA00007970A (en) Compositions and methods for treating allergic and inflammatory conditions with cough

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230113

WD01 Invention patent application deemed withdrawn after publication